Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii -pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

Guido Schäfer,Christian Hoffmann,Keikawus Arastéh,Dirk Schürmann,Christoph Stephan,Bjørn Jensen,Matthias Stoll,Johannes R. Bogner,Gerd Faetkenheuer,Jürgen K. Rockstroh,Hartwig Klinker,Georg Härter,Albrecht Stöhr,Olaf Degen,Eric Freiwald,Anja Hüfner,Sabine Jordan,Julian Schulze zur Wiesch,Marylyn M. Addo,Ansgar W. Lohse,Jan van Lunzen,Stefan Schmiedel

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii -pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

2019

Background To evaluate clinical outcomes after either immediate or deferred initiation of antiretroviral therapy in HIV-1-infected patients, presenting late with pneumocystis pneumonia (PCP) or toxoplasma encephalitis (TE).

Keywords:

Pneumocystis pneumonia
Quality of life
Toxoplasmosis
Immunology
Pneumocystis jirovecii Pneumonia
Immune reconstitution inflammatory syndrome
disease progression
Medicine
Internal medicine
Clinical endpoint
Clinical trial
HIV/AIDS
Pneumocystis jirovecii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations